Myriad Genetics, Inc. (FRA:MYD)

Market Cap	613.36M
Revenue (ttm)	703.40M
Net Income (ttm)	-341.35M
Shares Out	n/a
EPS (ttm)	-3.72
PE Ratio	n/a
Forward PE	288.82
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	17
Open	6.50
Previous Close	6.45
Day's Range	6.50 - 6.50
52-Week Range	3.30 - 15.70
Beta	n/a
RSI	56.47
Earnings Date	Feb 24, 2026

About Myriad Genetics

Myriad Genetics, Inc., a molecular diagnostic testing and precision medicine company, develops and provides molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious o...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1991
• Employees: 2,700
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: MYD

Financial Performance

In 2024, Myriad Genetics's revenue was $837.60 million, an increase of 11.21% compared to the previous year's $753.20 million. Losses were -$127.30 million, -51.65% less than in 2023.

Financial numbers in USD